JP7743504B2 - Ａｐｏｌ１の阻害剤およびこれを使用する方法 - Google Patents

Ａｐｏｌ１の阻害剤およびこれを使用する方法

Info

Publication number
JP7743504B2
JP7743504B2 JP2023513110A JP2023513110A JP7743504B2 JP 7743504 B2 JP7743504 B2 JP 7743504B2 JP 2023513110 A JP2023513110 A JP 2023513110A JP 2023513110 A JP2023513110 A JP 2023513110A JP 7743504 B2 JP7743504 B2 JP 7743504B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
optionally substituted
pharmaceutically acceptable
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023513110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539194A (ja
JP2023539194A5 (https=
Inventor
ジュン ミュン アン，
サマンサ アングル，
マイケル アーロン ブロドニー，
ジンロン ツァオ，
ジョン イー． コクラン，
ジョン エイチ． カム，
レスリー エー． デーキン，
エレナ ドルギフ，
ブラッド ディー． マクスウェル，
スガンティニ エス． ナンタクマール，
ハードウィン オダウド，
ジェシカ ハワード オルセン，
ティモシー ジェイ． センター，
アキラ ジョゼフ シミズ，
スティーブン デイビッド ストーン，
ハオシュアン ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2023539194A publication Critical patent/JP2023539194A/ja
Publication of JP2023539194A5 publication Critical patent/JP2023539194A5/ja
Priority to JP2025150349A priority Critical patent/JP2025183328A/ja
Application granted granted Critical
Publication of JP7743504B2 publication Critical patent/JP7743504B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023513110A 2020-08-26 2021-08-26 Ａｐｏｌ１の阻害剤およびこれを使用する方法 Active JP7743504B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150349A JP2025183328A (ja) 2020-08-26 2025-09-10 Ａｐｏｌ１の阻害剤およびこれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
US63/070,705 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150349A Division JP2025183328A (ja) 2020-08-26 2025-09-10 Ａｐｏｌ１の阻害剤およびこれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023539194A JP2023539194A (ja) 2023-09-13
JP2023539194A5 JP2023539194A5 (https=) 2024-08-30
JP7743504B2 true JP7743504B2 (ja) 2025-09-24

Family

ID=77822053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513110A Active JP7743504B2 (ja) 2020-08-26 2021-08-26 Ａｐｏｌ１の阻害剤およびこれを使用する方法
JP2025150349A Pending JP2025183328A (ja) 2020-08-26 2025-09-10 Ａｐｏｌ１の阻害剤およびこれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025150349A Pending JP2025183328A (ja) 2020-08-26 2025-09-10 Ａｐｏｌ１の阻害剤およびこれを使用する方法

Country Status (21)

Country Link
US (2) US11866446B2 (https=)
EP (1) EP4204423A1 (https=)
JP (2) JP7743504B2 (https=)
KR (1) KR20230057386A (https=)
CN (1) CN116547287B (https=)
AR (1) AR123355A1 (https=)
AU (1) AU2021333776A1 (https=)
BR (1) BR112023003423A2 (https=)
CA (1) CA3190609A1 (https=)
CL (1) CL2023000536A1 (https=)
CO (1) CO2023003026A2 (https=)
CR (1) CR20230132A (https=)
DO (1) DOP2023000042A (https=)
EC (1) ECSP23020167A (https=)
IL (2) IL318169A (https=)
JO (1) JOP20230035A1 (https=)
MX (1) MX2023002269A (https=)
PE (1) PE20231106A1 (https=)
SA (1) SA523442662B1 (https=)
UY (1) UY39395A (https=)
WO (1) WO2022047031A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) * 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
WO2024249252A1 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
AU2024343017A1 (en) 2023-09-11 2026-03-19 Vertex Pharmaceuticals Incorporated Process for preparing (2s,4s,4's,6s)-2-methyl-6-(1-methyl-1h-1,2,3-triazol-4-yl)-2',-(trieluoromethyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno [2,3-c] pyran] -4'-ol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507602A (ja) 2017-02-16 2020-03-12 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 統合失調症を処置する方法
WO2020131807A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
JP2007504221A (ja) 2003-09-03 2007-03-01 ガラパゴス・エヌブイ 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
JP5406722B2 (ja) 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
AU2010319400B2 (en) 2009-11-16 2013-12-19 Eli Lilly And Company Spiropiperidine compounds as ORL-1 receptor antagonists
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
WO2017137334A1 (en) 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
CA3156359A1 (en) 2019-11-08 2021-05-14 Adrian Liam Gill Bicyclic heteroaryl compounds and uses thereof
TW202136219A (zh) 2019-12-19 2021-10-01 美商卡司馬療法公司 Trpml調節劑
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
IL296423A (en) 2020-04-22 2022-11-01 Anima Biotech Inc Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
JP2023524563A (ja) 2020-05-07 2023-06-12 ラムバム メド－テック リミテッド Ａｐｏｌ１－関連疾患の治療に使用するための組成物
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
CN115996923B (zh) 2020-08-26 2025-07-18 海思科医药集团股份有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
EP4440697A1 (en) 2021-11-30 2024-10-09 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2023219516A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
CA3251050A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
CN119212986A (zh) 2022-02-08 2024-12-27 弗特克斯药品有限公司 作为apol1的抑制剂的螺哌啶衍生物及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507602A (ja) 2017-02-16 2020-03-12 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 統合失調症を処置する方法
WO2020131807A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
JP2023539194A (ja) 2023-09-13
PE20231106A1 (es) 2023-07-19
KR20230057386A (ko) 2023-04-28
BR112023003423A2 (pt) 2023-03-21
US20220106327A1 (en) 2022-04-07
IL300298B2 (en) 2025-06-01
JP2025183328A (ja) 2025-12-16
SA523442662B1 (ar) 2025-05-26
CN116547287B (zh) 2025-09-26
CA3190609A1 (en) 2022-03-03
CL2023000536A1 (es) 2023-09-08
IL300298A (en) 2023-04-01
AU2021333776A1 (en) 2023-03-16
EP4204423A1 (en) 2023-07-05
MX2023002269A (es) 2023-05-16
CN116547287A (zh) 2023-08-04
IL318169A (en) 2025-03-01
AR123355A1 (es) 2022-11-23
UY39395A (es) 2022-03-31
US11866446B2 (en) 2024-01-09
ECSP23020167A (es) 2023-12-29
WO2022047031A1 (en) 2022-03-03
JOP20230035A1 (ar) 2023-02-14
CO2023003026A2 (es) 2023-03-17
CR20230132A (es) 2023-06-27
US20240368180A1 (en) 2024-11-07
IL300298B1 (en) 2025-02-01
DOP2023000042A (es) 2023-07-09
US12421249B2 (en) 2025-09-23
TW202227456A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
JP7743504B2 (ja) Ａｐｏｌ１の阻害剤およびこれを使用する方法
AU2018392321B2 (en) Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CA2930414C (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
US10004737B2 (en) Fused imidazole and pyrazole derivatives as modulators of TNF activity
RU2679914C1 (ru) Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf
AU2014221489B2 (en) Tricyclic compound and use thereof
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
UA122433C2 (uk) Заміщена піперидинова сполука та її застосування
JP2025505647A (ja) Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法
JP2025505644A (ja) Ａｐｏｌ１の阻害剤としての４’，５’－ジヒドロスピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、及びそれを使用する方法
CA3178470A1 (en) Modulators of alpha-1 antitrypsin
KR20170129811A (ko) Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물
WO2016198401A1 (en) Indazole derivatives as modulators of tnf activity
KR0162637B1 (ko) 단백질 키나아제 c 억제제로서 유용한 신규 퀴놀릴옥사졸-2-온
EP4584261A1 (en) Modulators of alpha-1 antitrypsin
CN119156375A (zh) 双环杂环衍生物和相关用途
TWI915407B (zh) Ａｐｏｌ１抑制劑及其使用方法
OA21175A (en) Inhibitors of APOL1 and methods of using same.
CN121219264A (zh) 含有芳香双并环的化合物
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250910

R150 Certificate of patent or registration of utility model

Ref document number: 7743504

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150